Evidence map›Paper›PMID 34842781›Full record

ArticlePediatric reports2021

Ivabradine-Flecainide as Breakthrough Drug Combination for Congenital Junctional Ectopic Tachycardia: A Case Report and Literature Review.

Giovanni Maria Di Marco, Angelica De Nigris, Angela Pepe, Annamaria Pagano, Giangiacomo Di Nardo, Vincenzo Tipo

Open access · goldAbstract readCase Reports
In one paragraph

Article in Pediatric reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Practical compendium of antiarrhythmic drugs: a clinical consensus statement of the European Heart Rhythm Association of the European Society of Cardiology.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Review
  2. Article
  3. [Research progress in the application of ivabradine in children with cardiovascular diseases].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2024
    Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Giovanni Maria Di MarcoDivision of Cardiology, Department of Pediatrics, Santobono- Pausilipon Children Medical Hospital, 80129 Naples, Italy.
Angelica De NigrisDepartment of Woman, Child and General and Specialist Surgery, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.ORCID 0000-0002-9594-2898
Angela PepeDepartment of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", Pediatrics Section, University of Salerno, 84081 Baronissi, Italy.ORCID 0000-0002-5801-0397
Annamaria PaganoDepartment of Translational Medical Science, Pediatrics Section, University of Naples "Federico II", 80126 Naples, Italy.
Giangiacomo Di NardoDivision of Cardiology, Department of Pediatrics, Santobono- Pausilipon Children Medical Hospital, 80129 Naples, Italy.
Vincenzo TipoPediatric Emergency and Short Stay Unit, Santobono-Pausilipon Children's Hospital, 80129 Naples, Italy.
Santobono Children's Hospital · ITUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Naples Federico II · ITUniversity of Salerno · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Congenital junctional ectopic tachycardia (CJET) is a rare tachyarrhythmia that remains difficult to manage, with suboptimal control in most cases. Here, we report literature research on the use of ivabradine in the treatment of pediatric junctional ectopic tachycardia (JET), both congenital and postoperative, and describe the successful use of ivabradine-flecainide association for CJET therapy resistant to other antiarrhythmic agents. This new drug combination was effective in completely suppressing JET. Ivabradine-flecainide combination may be considered a new therapeutic strategy of CJET with a satisfactory efficacy/tolerability ratio in patients resistant to conventional drug combinations.

Indexed as

congenitalivabradinejunctionalpediatricstachycardia

Identifiers

PMID34842781
PMCPMC8629013
OpenAlexW3216423851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.